Aptevo Therapeutics Inc.
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | 71.00K | -345.00K | -- |
| Gross Profit | -- | -- | -71.00K | 345.00K | -- |
| SG&A Expenses | 3.57M | 2.90M | 2.85M | 2.50M | 2.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.61M | 6.23M | 6.48M | 6.38M | 5.21M |
| Operating Income | -7.61M | -6.23M | -6.48M | -6.38M | -5.21M |
| Income Before Tax | -7.55M | -6.20M | -6.41M | -6.31M | -5.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.55M | -6.20M | -6.41M | -6.31M | -5.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.55M | -6.20M | -6.41M | -6.31M | -5.10M |
| EBIT | -7.61M | -6.23M | -6.48M | -6.38M | -5.21M |
| EBITDA | -7.56M | -6.18M | -6.42M | -6.31M | -5.13M |
| EPS Basic | -40.13 | -151.29 | -- | -- | -- |
| Normalized Basic EPS | -20.97 | -94.55 | -- | -- | -- |
| EPS Diluted | -40.13 | -151.29 | -- | -- | -- |
| Normalized Diluted EPS | -20.97 | -94.55 | -- | -- | -- |
| Average Basic Shares Outstanding | 224.90K | 41.00K | -- | -- | -- |
| Average Diluted Shares Outstanding | 224.90K | 41.00K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |